September 22, 2026
Blinatumomab (BLINCYTO) is a NIOSH Table 2 hazardous drug that qualifies for a documented Assessment of Risk (AOR) rather than full USP <800> containment, since no manufacturer CSTD compatibility data exist. This standard provides organizations with a risk-based framework for establishing appropriate handling practices. It guides facilities through considerations such as confirming NIOSH status, annual review by the Designated Person, receiving and storage, compounding practices and PPE, dedicated-line administration, and spill, waste, and transport procedures. The framework is designed to help each organization establish, document, and justify its containment and handling decisions.
NHIA is requesting that public stakeholders review and provide feedback on the draft practice standard. Your comments on proposed practice standards play a key role in the standards development process. You can comment on all text published within the practice standard section of the following document:
The comment period closes October 23, 2026.
The target audience includes clinicians, regulatory agencies, reimbursement professionals, and industry stakeholders.
Please submit all comments to standards@nhia.org.